Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disorder that can affect virtually any organ of the body. In lupus, the body's immune system, which normally functions to protect against foreign invaders, becomes hyperactive, forming antibodies that attack normal tissues and organs, including the skin, joints, kidneys, brain, heart, lungs, and blood. Lupus is characterized by periods of illness, called flares, and periods of wellness or remission. Because its symptoms come and go and mimic those of other diseases, lupus is difficult to diagnose. There is no single laboratory test that can definitively prove that a person has the complex illness.To date, lupus has no known cause or cure. Early detection and treatment are the key to a better health outcome and can usually lessen the progression and severity of the disease. Anti-inflammatory drugs, antimalarials, and steroids (such as cortisone and others) are often used to treat lupus. Cytotoxic chemotherapies, like those used in the treatment of cancer, are also used to suppress the immune system in lupus patients. A new edition of this established and well-regarded reference combines basic science with clinical science to provide a translational medicine model. Systemic Lupus Erythematosus, Sixth Edition, is a useful reference for specialists in the diagnosis and management of patients with SLE, a tool for measurement of clinical activity for pharmaceutical development and basic research of the disease, and a reference work for hospital libraries.
- Completely updated, revised, and expanded with the most comprehensive and accessible reference on SLE for clinicians and scientists
- Full-color presentation throughout the book
- Provides the latest information available on diagnosis and treatment
- Incorporates an international panel of authors who are experts in their fields, with an emphasis on young, cutting-edge scientists and physicians
Auflage
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science & Techn.
Dateigröße
ISBN-13
978-0-323-91488-8 (9780323914888)
Schweitzer Klassifikation
Part I: Basis of the DiseaseSection A: Genetics and epigenetics1. Major histocompatibility complex and SLE2. Lupus Susceptibility genes3. Epigenetics in systemic lupus erythematosus and the integration of molecular pathways
Section B: Immunopathogenesis4. Autoantigens, antigenic mimicry, and immune complexes5. B-cell Biology, tolerance and autoantibodies6. T-Cell Biology, tolerance and regulation7. Polymorphonuclear cells8. Metabolic and mitochondrial dysfunction in SLE9. Immunopathogenesis: the role of mucosal and skin microbiota in SLE
Section C: Disease effectors and modifiers10. Complement and SLE11. Interferons and cytokines in SLE pathogenesis and therapy12. Innate immunity in SLE pathogenesis13. Sex bias in SLE
Section D: Tissue injury-the Biology14. Mechanisms of tissue injury in lupus nephritis15. The skin16. The brain in SLE: mechanisms and detection of injury and therapeutic strategies17. The role of infections in SLE pathogenesis18. Tissue injurydthe biology: SLE-associated vascular disease and antiphospholipid syndrome
Part II: Clinical presentation of diseaseSection A: Clinical presentation19. Epidemiology of SLE and related diseases: incidence, prevalence, and mortality20. The clinical presentation of systemic lupus erythematosus and laboratory diagnosis21. Passively acquired lupus in the fetus and neonate22. Systemic lupus erythematosus in children23. Environmental and drug-induced lupus24. Reproductive health25. Monitoring disease activity26. Overlap syndromes
Section B: Specific organ involvement and clinical presentation27. Nervous system28. Skin29. Kidney disease30. Cardiovascular disease in lupus31. Pulmonary manifestations of systemic lupus erythematosus32. GI hepatic and nonhepatic diseases33. Musculoskeletal system: articular disease, myositis, and bone metabolism34. Clinical presentation of antiphospholipid syndrome35. Hematology: cytopenias36. Malignancy risk and screening
Section C: Treatment of systemic llupus erythematosus37. Antimalarial drugs (and lupus)38. Glucocorticoids39. Immunosuppressive therapy in SLE40. Pipeline therapies and future drug development41. Challenges of systemic lupus clinical trials
